There are multiple factors that restrict the use of PD-L1 expression as a predictive biomarker, such as the variation in PD-L1 expression within the tumor itself, the inconsistency in PD-L1 expression between primary tumors and metastases, and the absence of standardized criteria for evaluating PD-L1 expression [87]. The gene discussed is CD274; the disease is neoplasm.